English

ABIOMED, Inc.

EDGAR

ABMD Quarterly report (10-Q) · filed 2022-11-03

261 filing records in this dataset, filed from 1995-03-30 to 2022-11-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

266 million USD

2023 Q2 · USD

Exact inputs and evidence

Revenue: 265921000 USD Source

Operating margin

21.81%

2023 Q2 · %

Exact inputs and evidence

Operating Income: 57994000 USD Source
Revenue: 265921000 USD Source

Operating cash flow

13.4 million USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 81524000 USD Source
Operating Cash Flow: 68103000 USD Source

Free cash flow

7.81 million USD

2023 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 81524000 USD Source
Operating Cash Flow: 68103000 USD Source
Capital Expenditure: 12392000 USD Source
Capital Expenditure: 6783000 USD Source

Cash and cash equivalents: 182 million USD 2022-09-30 Source
Exact value

182335000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 45.2 million shares 2022-09-30 Source
Exact value

45172000 shares

Reported share-count change

-0.71% · -325 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

45496563 shares · 2021-09-30· Source
45172000 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

1.07 billion USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 261176000 USD · 2021-10-01 – 2021-12-31 Source
Revenue: 1031753000 USD · 2021-04-01 – 2022-03-31 Source
Revenue: 761903000 USD · 2021-04-01 – 2021-12-31 Source
Revenue: 277149000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 265921000 USD · 2022-07-01 – 2022-09-30 Source

Net income

267 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: 45752000 USD · 2021-10-01 – 2021-12-31 Source
Net income: 136505000 USD · 2021-04-01 – 2022-03-31 Source
Net income: 76180000 USD · 2021-04-01 – 2021-12-31 Source
Net income: 54554000 USD · 2022-04-01 – 2022-06-30 Source
Net income: 106133000 USD · 2022-07-01 – 2022-09-30 Source

Operating cash flow

251 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: 206418000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: 115931000 USD · 2021-04-01 – 2021-09-30 Source
Operating cash flow: 285390000 USD · 2021-04-01 – 2022-03-31 Source
Operating cash flow: 206418000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: 68103000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: 81524000 USD · 2022-04-01 – 2022-09-30 Source
Operating cash flow: 68103000 USD · 2022-04-01 – 2022-06-30 Source

Capital expenditure

33.8 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 20872000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 14394000 USD · 2021-04-01 – 2021-09-30 Source
Capital expenditure: 35763000 USD · 2021-04-01 – 2022-03-31 Source
Capital expenditure: 20872000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 6783000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 12392000 USD · 2022-04-01 – 2022-09-30 Source
Capital expenditure: 6783000 USD · 2022-04-01 – 2022-06-30 Source

Free cash flow

217 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: 206418000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: 115931000 USD · 2021-04-01 – 2021-09-30 Source
Operating cash flow: 285390000 USD · 2021-04-01 – 2022-03-31 Source
Operating cash flow: 206418000 USD · 2021-04-01 – 2021-12-31 Source
Operating cash flow: 68103000 USD · 2022-04-01 – 2022-06-30 Source
Operating cash flow: 81524000 USD · 2022-04-01 – 2022-09-30 Source
Operating cash flow: 68103000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 20872000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 14394000 USD · 2021-04-01 – 2021-09-30 Source
Capital expenditure: 35763000 USD · 2021-04-01 – 2022-03-31 Source
Capital expenditure: 20872000 USD · 2021-04-01 – 2021-12-31 Source
Capital expenditure: 6783000 USD · 2022-04-01 – 2022-06-30 Source
Capital expenditure: 12392000 USD · 2022-04-01 – 2022-09-30 Source
Capital expenditure: 6783000 USD · 2022-04-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-03.

Financial data available through: 2022-03-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2022-03-31
Operating income: 11 of 11 periods available· newest 2022-03-31
Net income: 11 of 11 periods available· newest 2022-03-31
Operating cash flow: 11 of 11 periods available· newest 2022-03-31
Capital expenditure: 11 of 11 periods available· newest 2022-03-31
Total assets: 11 of 11 periods available· newest 2022-03-31
Total liabilities: 11 of 11 periods available· newest 2022-03-31
Current assets: 11 of 11 periods available· newest 2022-03-31
Current liabilities: 11 of 11 periods available· newest 2022-03-31
Cash and cash equivalents: 11 of 11 periods available· newest 2022-03-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2022-03-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+21.7%

Prior period

USD 847.52 million

2020-04-01 – 2021-03-31
Current period

USD 1.03 billion

2021-04-01 – 2022-03-31

Exact inputs and evidence

1031753000 − 847522000 = 184231000 USD

847522000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
1031753000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Year-over-year change in Revenue: 184231000 USD Concept: fundies:Revenue Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 1031753000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#3151898 Filing: 000095017022010402 Input fundies:Revenue: 847522000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#3153988 Filing: 000095017022010402
The citation records this snapshot. The page link may show a newer release later.
Net income
-39.5%

Prior period

USD 225.53 million

2020-04-01 – 2021-03-31
Current period

USD 136.51 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

136505000 − 225525000 = -89020000 USD

225525000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
136505000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Year-over-year change in Net income: -89020000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 136505000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2947181 Filing: 000095017022010402 Input fundies:NetIncome: 225525000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2949106 Filing: 000095017022010402
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+3.9%

Prior period

USD 274.58 million

2020-04-01 – 2021-03-31
Current period

USD 285.39 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

285390000 − 274578000 = 10812000 USD

274578000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
285390000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Year-over-year change in Operating cash flow: 10812000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 285390000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2654594 Filing: 000095017022010402 Input fundies:OperatingCashFlow: 274578000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2656459 Filing: 000095017022010402
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-33%

Prior period

USD 53.38 million

2020-04-01 – 2021-03-31
Current period

USD 35.76 million

2021-04-01 – 2022-03-31

Exact inputs and evidence

35763000 − 53383000 = -17620000 USD

53383000 USD · 2020-04-01 – 2021-03-31
Inspect prior input Prior source
35763000 USD · 2021-04-01 – 2022-03-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Year-over-year change in Capital expenditure: -17620000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 35763000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2702238 Filing: 000095017022010402 Input fundies:CapitalExpenditure: 53383000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2704502 Filing: 000095017022010402
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2022 2021-04-01 – 2022-03-31

Revenue USD 1.03 billion 100% of revenue
Cost of revenue USD 188.16 million 18% of revenue
Operating expenses USD 586.89 million 57% of revenue
Other operating costs Derived USD 115.99 million 11% of revenue
Operating income USD 140.72 million 14% of revenue
Tax, interest and other Derived USD 4.22 million 0.4% of revenue
Net income USD 136.51 million 13% of revenue

Cash

Operating cash flow USD 285.39 million 28% of revenue
Capital expenditure USD 35.76 million 3.5% of revenue
Free cash flow Derived USD 249.63 million 24% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 9.5%90%
2014 95%
2015 Net income was higher than operating income, so the split is not drawn.
2016 12%80%
2017 12%80%
2018 19%74%
2019 Net income was higher than operating income, so the split is not drawn.
2020 24%70%
2021 27%73%
2022 13%86%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2012-04-01 – 2013-03-31	158124000	141581000 Derived	16543000	1529000 Derived	15014000	23563000 Derived	Source 2012-04-01 – 2013-03-31: 158124000 USD Inspect Revenue Open source 2012-04-01 – 2013-03-31: 16543000 USD Inspect Operating Income Open source 2012-04-01 – 2013-03-31: 15014000 USD Inspect Net Income Open source 2012-04-01 – 2013-03-31: 26399000 USD Inspect Operating Cash Flow Open source 2012-04-01 – 2013-03-31: 2836000 USD Inspect Capital Expenditure Open source
2014 2013-04-01 – 2014-03-31	183643000	175280000 Derived	8363000	1012000 Derived	7351000	20705000 Derived	Source 2013-04-01 – 2014-03-31: 183643000 USD Inspect Revenue Open source 2013-04-01 – 2014-03-31: 8363000 USD Inspect Operating Income Open source 2013-04-01 – 2014-03-31: 7351000 USD Inspect Net Income Open source 2013-04-01 – 2014-03-31: 23466000 USD Inspect Operating Cash Flow Open source 2013-04-01 – 2014-03-31: 2761000 USD Inspect Capital Expenditure Open source
2015 2014-04-01 – 2015-03-31	230311000	201645000 Derived	28666000	-85022000 Derived	113688000	38102000 Derived	Source 2014-04-01 – 2015-03-31: 230311000 USD Inspect Revenue Open source 2014-04-01 – 2015-03-31: 28666000 USD Inspect Operating Income Open source 2014-04-01 – 2015-03-31: 113688000 USD Inspect Net Income Open source 2014-04-01 – 2015-03-31: 43290000 USD Inspect Operating Cash Flow Open source 2014-04-01 – 2015-03-31: 5188000 USD Inspect Capital Expenditure Open source
2016 2015-04-01 – 2016-03-31	329543000	264439000 Derived	65104000	26957000 Derived	38147000	61171000 Derived	Source 2015-04-01 – 2016-03-31: 329543000 USD Inspect Revenue Open source 2015-04-01 – 2016-03-31: 65104000 USD Inspect Operating Income Open source 2015-04-01 – 2016-03-31: 38147000 USD Inspect Net Income Open source 2015-04-01 – 2016-03-31: 76795000 USD Inspect Operating Cash Flow Open source 2015-04-01 – 2016-03-31: 15624000 USD Inspect Capital Expenditure Open source
2017 2016-04-01 – 2017-03-31	445304000	355166000 Derived	90138000	38022000 Derived	52116000	64701000 Derived	Source 2016-04-01 – 2017-03-31: 445304000 USD Inspect Revenue Open source 2016-04-01 – 2017-03-31: 90138000 USD Inspect Operating Income Open source 2016-04-01 – 2017-03-31: 52116000 USD Inspect Net Income Open source 2016-04-01 – 2017-03-31: 115116000 USD Inspect Operating Cash Flow Open source 2016-04-01 – 2017-03-31: 50415000 USD Inspect Capital Expenditure Open source
2018 2017-04-01 – 2018-03-31	593749000	436612000 Derived	157137000	44967000 Derived	112170000	136683000 Derived	Source 2017-04-01 – 2018-03-31: 593749000 USD Inspect Revenue Open source 2017-04-01 – 2018-03-31: 157137000 USD Inspect Operating Income Open source 2017-04-01 – 2018-03-31: 112170000 USD Inspect Net Income Open source 2017-04-01 – 2018-03-31: 192546000 USD Inspect Operating Cash Flow Open source 2017-04-01 – 2018-03-31: 55863000 USD Inspect Capital Expenditure Open source
2019 2018-04-01 – 2019-03-31	769432000	544620000 Derived	224812000	-34204000 Derived	259016000	208193000 Derived	Source 2018-04-01 – 2019-03-31: 769432000 USD Inspect Revenue Open source 2018-04-01 – 2019-03-31: 224812000 USD Inspect Operating Income Open source 2018-04-01 – 2019-03-31: 259016000 USD Inspect Net Income Open source 2018-04-01 – 2019-03-31: 252197000 USD Inspect Operating Cash Flow Open source 2018-04-01 – 2019-03-31: 44004000 USD Inspect Capital Expenditure Open source
2020 2019-04-01 – 2020-03-31	840883000	591664000 Derived	249219000	46210000 Derived	203009000	270914000 Derived	Source 2019-04-01 – 2020-03-31: 840883000 USD Inspect Revenue Open source 2019-04-01 – 2020-03-31: 249219000 USD Inspect Operating Income Open source 2019-04-01 – 2020-03-31: 203009000 USD Inspect Net Income Open source 2019-04-01 – 2020-03-31: 314920000 USD Inspect Operating Cash Flow Open source 2019-04-01 – 2020-03-31: 44006000 USD Inspect Capital Expenditure Open source
2021 2020-04-01 – 2021-03-31	847522000	617965000 Derived	229557000	4032000 Derived	225525000	221195000 Derived	Source 2020-04-01 – 2021-03-31: 847522000 USD Inspect Revenue Open source 2020-04-01 – 2021-03-31: 229557000 USD Inspect Operating Income Open source 2020-04-01 – 2021-03-31: 225525000 USD Inspect Net Income Open source 2020-04-01 – 2021-03-31: 274578000 USD Inspect Operating Cash Flow Open source 2020-04-01 – 2021-03-31: 53383000 USD Inspect Capital Expenditure Open source
2022 2021-04-01 – 2022-03-31	1031753000	891033000 Derived	140720000	4215000 Derived	136505000	249627000 Derived	Source 2021-04-01 – 2022-03-31: 1031753000 USD Inspect Revenue Open source 2021-04-01 – 2022-03-31: 140720000 USD Inspect Operating Income Open source 2021-04-01 – 2022-03-31: 136505000 USD Inspect Net Income Open source 2021-04-01 – 2022-03-31: 285390000 USD Inspect Operating Cash Flow Open source 2021-04-01 – 2022-03-31: 35763000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 1B 2022

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-03-31	Revenue	158124000	Revenue: 158124000 Open source
20142014-03-31	Revenue	183643000	Revenue: 183643000 Open source
20152015-03-31	Revenue	230311000	Revenue: 230311000 Open source
20162016-03-31	Revenue	329543000	Revenue: 329543000 Open source
20172017-03-31	Revenue	445304000	Revenue: 445304000 Open source
20182018-03-31	Revenue	593749000	Revenue: 593749000 Open source
20192019-03-31	Revenue	769432000	Revenue: 769432000 Open source
20202020-03-31	Revenue	840883000	Revenue: 840883000 Open source
20212021-03-31	Revenue	847522000	Revenue: 847522000 Open source
20222022-03-31	Revenue	1031753000	Revenue: 1031753000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

21.7% 2022

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-03-31	Year over year	25.1%	Revenue: 158124000 Open source Revenue: 126375000 Open source
20142014-03-31	Year over year	16.1%	Revenue: 183643000 Open source Revenue: 158124000 Open source
20152015-03-31	Year over year	25.4%	Revenue: 230311000 Open source Revenue: 183643000 Open source
20162016-03-31	Year over year	43.1%	Revenue: 329543000 Open source Revenue: 230311000 Open source
20172017-03-31	Year over year	35.1%	Revenue: 445304000 Open source Revenue: 329543000 Open source
20182018-03-31	Year over year	33.3%	Revenue: 593749000 Open source Revenue: 445304000 Open source
20192019-03-31	Year over year	29.6%	Revenue: 769432000 Open source Revenue: 593749000 Open source
20202020-03-31	Year over year	9.3%	Revenue: 840883000 Open source Revenue: 769432000 Open source
20212021-03-31	Year over year	0.8%	Revenue: 847522000 Open source Revenue: 840883000 Open source
20222022-03-31	Year over year	21.7%	Revenue: 1031753000 Open source Revenue: 847522000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 13.6% 2022

Net margin 13.2% 2022

Free cash flow margin 24.2% 2022

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-03-31	Operating margin	10.5%	Operating Income: 16543000 Open source Revenue: 158124000 Open source
20142014-03-31	Operating margin	4.6%	Operating Income: 8363000 Open source Revenue: 183643000 Open source
20152015-03-31	Operating margin	12.4%	Operating Income: 28666000 Open source Revenue: 230311000 Open source
20162016-03-31	Operating margin	19.8%	Operating Income: 65104000 Open source Revenue: 329543000 Open source
20172017-03-31	Operating margin	20.2%	Operating Income: 90138000 Open source Revenue: 445304000 Open source
20182018-03-31	Operating margin	26.5%	Operating Income: 157137000 Open source Revenue: 593749000 Open source
20192019-03-31	Operating margin	29.2%	Operating Income: 224812000 Open source Revenue: 769432000 Open source
20202020-03-31	Operating margin	29.6%	Operating Income: 249219000 Open source Revenue: 840883000 Open source
20212021-03-31	Operating margin	27.1%	Operating Income: 229557000 Open source Revenue: 847522000 Open source
20222022-03-31	Operating margin	13.6%	Operating Income: 140720000 Open source Revenue: 1031753000 Open source
20132013-03-31	Net margin	9.5%	Net Income: 15014000 Open source Revenue: 158124000 Open source
20142014-03-31	Net margin	4%	Net Income: 7351000 Open source Revenue: 183643000 Open source
20152015-03-31	Net margin	49.4%	Net Income: 113688000 Open source Revenue: 230311000 Open source
20162016-03-31	Net margin	11.6%	Net Income: 38147000 Open source Revenue: 329543000 Open source
20172017-03-31	Net margin	11.7%	Net Income: 52116000 Open source Revenue: 445304000 Open source
20182018-03-31	Net margin	18.9%	Net Income: 112170000 Open source Revenue: 593749000 Open source
20192019-03-31	Net margin	33.7%	Net Income: 259016000 Open source Revenue: 769432000 Open source
20202020-03-31	Net margin	24.1%	Net Income: 203009000 Open source Revenue: 840883000 Open source
20212021-03-31	Net margin	26.6%	Net Income: 225525000 Open source Revenue: 847522000 Open source
20222022-03-31	Net margin	13.2%	Net Income: 136505000 Open source Revenue: 1031753000 Open source
20132013-03-31	Free cash flow margin	14.9%	Revenue: 158124000 Open source Operating Cash Flow: 26399000 Open source Capital Expenditure: 2836000 Open source
20142014-03-31	Free cash flow margin	11.3%	Revenue: 183643000 Open source Operating Cash Flow: 23466000 Open source Capital Expenditure: 2761000 Open source
20152015-03-31	Free cash flow margin	16.5%	Revenue: 230311000 Open source Operating Cash Flow: 43290000 Open source Capital Expenditure: 5188000 Open source
20162016-03-31	Free cash flow margin	18.6%	Revenue: 329543000 Open source Operating Cash Flow: 76795000 Open source Capital Expenditure: 15624000 Open source
20172017-03-31	Free cash flow margin	14.5%	Revenue: 445304000 Open source Operating Cash Flow: 115116000 Open source Capital Expenditure: 50415000 Open source
20182018-03-31	Free cash flow margin	23%	Revenue: 593749000 Open source Operating Cash Flow: 192546000 Open source Capital Expenditure: 55863000 Open source
20192019-03-31	Free cash flow margin	27.1%	Revenue: 769432000 Open source Operating Cash Flow: 252197000 Open source Capital Expenditure: 44004000 Open source
20202020-03-31	Free cash flow margin	32.2%	Revenue: 840883000 Open source Operating Cash Flow: 314920000 Open source Capital Expenditure: 44006000 Open source
20212021-03-31	Free cash flow margin	26.1%	Revenue: 847522000 Open source Operating Cash Flow: 274578000 Open source Capital Expenditure: 53383000 Open source
20222022-03-31	Free cash flow margin	24.2%	Revenue: 1031753000 Open source Operating Cash Flow: 285390000 Open source Capital Expenditure: 35763000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 285.4M 2022

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-03-31	Operating cash flow	26399000	Operating Cash Flow: 26399000 Open source
20142014-03-31	Operating cash flow	23466000	Operating Cash Flow: 23466000 Open source
20152015-03-31	Operating cash flow	43290000	Operating Cash Flow: 43290000 Open source
20162016-03-31	Operating cash flow	76795000	Operating Cash Flow: 76795000 Open source
20172017-03-31	Operating cash flow	115116000	Operating Cash Flow: 115116000 Open source
20182018-03-31	Operating cash flow	192546000	Operating Cash Flow: 192546000 Open source
20192019-03-31	Operating cash flow	252197000	Operating Cash Flow: 252197000 Open source
20202020-03-31	Operating cash flow	314920000	Operating Cash Flow: 314920000 Open source
20212021-03-31	Operating cash flow	274578000	Operating Cash Flow: 274578000 Open source
20222022-03-31	Operating cash flow	285390000	Operating Cash Flow: 285390000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD 249.6M 2022

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-03-31	Free cash flow	23563000	Operating Cash Flow: 26399000 Open source Capital Expenditure: 2836000 Open source
20142014-03-31	Free cash flow	20705000	Operating Cash Flow: 23466000 Open source Capital Expenditure: 2761000 Open source
20152015-03-31	Free cash flow	38102000	Operating Cash Flow: 43290000 Open source Capital Expenditure: 5188000 Open source
20162016-03-31	Free cash flow	61171000	Operating Cash Flow: 76795000 Open source Capital Expenditure: 15624000 Open source
20172017-03-31	Free cash flow	64701000	Operating Cash Flow: 115116000 Open source Capital Expenditure: 50415000 Open source
20182018-03-31	Free cash flow	136683000	Operating Cash Flow: 192546000 Open source Capital Expenditure: 55863000 Open source
20192019-03-31	Free cash flow	208193000	Operating Cash Flow: 252197000 Open source Capital Expenditure: 44004000 Open source
20202020-03-31	Free cash flow	270914000	Operating Cash Flow: 314920000 Open source Capital Expenditure: 44006000 Open source
20212021-03-31	Free cash flow	221195000	Operating Cash Flow: 274578000 Open source Capital Expenditure: 53383000 Open source
20222022-03-31	Free cash flow	249627000	Operating Cash Flow: 285390000 Open source Capital Expenditure: 35763000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

10.2% 2022

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-03-31	Liabilities / assets	19.4%	Total Liabilities: 32919000 Open source Total Assets: 169999000 Open source
20142014-03-31	Liabilities / assets	18%	Total Liabilities: 37054000 Open source Total Assets: 205407000 Open source
20152015-03-31	Liabilities / assets	13.8%	Total Liabilities: 46807000 Open source Total Assets: 338367000 Open source
20162016-03-31	Liabilities / assets	13%	Total Liabilities: 55156000 Open source Total Assets: 423931000 Open source
20172017-03-31	Liabilities / assets	17.9%	Total Liabilities: 98343000 Open source Total Assets: 550414000 Open source
20182018-03-31	Liabilities / assets	12.3%	Total Liabilities: 96851000 Open source Total Assets: 786375000 Open source
20192019-03-31	Liabilities / assets	11.1%	Total Liabilities: 117456000 Open source Total Assets: 1054346000 Open source
20202020-03-31	Liabilities / assets	12.4%	Total Liabilities: 150996000 Open source Total Assets: 1216462000 Open source
20212021-03-31	Liabilities / assets	11%	Total Liabilities: 164684000 Open source Total Assets: 1494359000 Open source
20222022-03-31	Liabilities / assets	10.2%	Total Liabilities: 170067000 Open source Total Assets: 1673393000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

7.05× 2022

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-03-31	Current assets / current liabilities	4.31×	Current Assets: 116605000 Open source Current Liabilities: 27056000 Open source
20142014-03-31	Current assets / current liabilities	3.88×	Current Assets: 117966000 Open source Current Liabilities: 30411000 Open source
20152015-03-31	Current assets / current liabilities	4.71×	Current Assets: 185039000 Open source Current Liabilities: 39319000 Open source
20162016-03-31	Current assets / current liabilities	6.2×	Current Assets: 288392000 Open source Current Liabilities: 46541000 Open source
20172017-03-31	Current assets / current liabilities	4.7×	Current Assets: 326958000 Open source Current Liabilities: 69617000 Open source
20182018-03-31	Current assets / current liabilities	5.84×	Current Assets: 494271000 Open source Current Liabilities: 84682000 Open source
20192019-03-31	Current assets / current liabilities	6.39×	Current Assets: 677197000 Open source Current Liabilities: 105998000 Open source
20202020-03-31	Current assets / current liabilities	4.82×	Current Assets: 635863000 Open source Current Liabilities: 131885000 Open source
20212021-03-31	Current assets / current liabilities	6.11×	Current Assets: 787965000 Open source Current Liabilities: 128969000 Open source
20222022-03-31	Current assets / current liabilities	7.05×	Current Assets: 976473000 Open source Current Liabilities: 138457000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2012-04-01 – 2013-03-31	USD 15.01 million Exact value Exact value: 15014000 USD 2012-04-01 – 2013-03-31: 15014000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2013-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 15014000 USD Concept: fundies:NetIncome Period: 2012-04-01 to 2013-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2013-03-31&surface=latest&period_type=duration&start=2012-04-01&unit=USD&dimensions= Input fundies:NetIncome: 15014000 USD (2012-04-01 to 2013-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000119312515204302/abmd-20150331.xml#99868 Filing: 000119312515204302 The citation records this snapshot. The page link may show a newer release later.	USD 26.4 million Exact value Exact value: 26399000 USD 2012-04-01 – 2013-03-31: 26399000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2013-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 26399000 USD Concept: fundies:OperatingCashFlow Period: 2012-04-01 to 2013-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2013-03-31&surface=latest&period_type=duration&start=2012-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26399000 USD (2012-04-01 to 2013-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000119312515204302/abmd-20150331.xml#88922 Filing: 000119312515204302 The citation records this snapshot. The page link may show a newer release later.	USD 2.84 million Exact value Exact value: 2836000 USD 2012-04-01 – 2013-03-31: 2836000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2013-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 2836000 USD Concept: fundies:CapitalExpenditure Period: 2012-04-01 to 2013-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2013-03-31&surface=latest&period_type=duration&start=2012-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2836000 USD (2012-04-01 to 2013-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000119312515204302/abmd-20150331.xml#99602 Filing: 000119312515204302 The citation records this snapshot. The page link may show a newer release later.	USD 23.56 million Calculation and evidence 26399000 − 2836000 USD Exact free cash flow: 23563000 USD 2012-04-01 – 2013-03-31: 26399000 USD · Inspect Operating Cash Flow · Source 2012-04-01 – 2013-03-31: 2836000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2013-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 23563000 USD Concept: free-cash-flow Period: 2012-04-01 to 2013-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26399000 USD (2012-04-01 to 2013-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000119312515204302/abmd-20150331.xml#88922 Filing: 000119312515204302 Input fundies:CapitalExpenditure: 2836000 USD (2012-04-01 to 2013-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000119312515204302/abmd-20150331.xml#99602 Filing: 000119312515204302 The citation records this snapshot. The page link may show a newer release later.
2014 2013-04-01 – 2014-03-31	USD 7.35 million Exact value Exact value: 7351000 USD 2013-04-01 – 2014-03-31: 7351000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2014-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 7351000 USD Concept: fundies:NetIncome Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:NetIncome: 7351000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459016020014/abmd-20160331.xml#123593 Filing: 000156459016020014 The citation records this snapshot. The page link may show a newer release later.	USD 23.47 million Exact value Exact value: 23466000 USD 2013-04-01 – 2014-03-31: 23466000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2014-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 23466000 USD Concept: fundies:OperatingCashFlow Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 23466000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459016020014/abmd-20160331.xml#162784 Filing: 000156459016020014 The citation records this snapshot. The page link may show a newer release later.	USD 2.76 million Exact value Exact value: 2761000 USD 2013-04-01 – 2014-03-31: 2761000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2014-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 2761000 USD Concept: fundies:CapitalExpenditure Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2014-03-31&surface=latest&period_type=duration&start=2013-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2761000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459016020014/abmd-20160331.xml#165525 Filing: 000156459016020014 The citation records this snapshot. The page link may show a newer release later.	USD 20.71 million Calculation and evidence 23466000 − 2761000 USD Exact free cash flow: 20705000 USD 2013-04-01 – 2014-03-31: 23466000 USD · Inspect Operating Cash Flow · Source 2013-04-01 – 2014-03-31: 2761000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2014-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 20705000 USD Concept: free-cash-flow Period: 2013-04-01 to 2014-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 23466000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459016020014/abmd-20160331.xml#162784 Filing: 000156459016020014 Input fundies:CapitalExpenditure: 2761000 USD (2013-04-01 to 2014-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459016020014/abmd-20160331.xml#165525 Filing: 000156459016020014 The citation records this snapshot. The page link may show a newer release later.
2015 2014-04-01 – 2015-03-31	USD 113.69 million Exact value Exact value: 113688000 USD 2014-04-01 – 2015-03-31: 113688000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2015-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 113688000 USD Concept: fundies:NetIncome Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:NetIncome: 113688000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459017011690/abmd-20170331.xml#140211 Filing: 000156459017011690 The citation records this snapshot. The page link may show a newer release later.	USD 43.29 million Exact value Exact value: 43290000 USD 2014-04-01 – 2015-03-31: 43290000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2015-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 43290000 USD Concept: fundies:OperatingCashFlow Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 43290000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459017011690/abmd-20170331.xml#180922 Filing: 000156459017011690 The citation records this snapshot. The page link may show a newer release later.	USD 5.19 million Exact value Exact value: 5188000 USD 2014-04-01 – 2015-03-31: 5188000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2015-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 5188000 USD Concept: fundies:CapitalExpenditure Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2015-03-31&surface=latest&period_type=duration&start=2014-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5188000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459017011690/abmd-20170331.xml#183667 Filing: 000156459017011690 The citation records this snapshot. The page link may show a newer release later.	USD 38.1 million Calculation and evidence 43290000 − 5188000 USD Exact free cash flow: 38102000 USD 2014-04-01 – 2015-03-31: 43290000 USD · Inspect Operating Cash Flow · Source 2014-04-01 – 2015-03-31: 5188000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2015-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 38102000 USD Concept: free-cash-flow Period: 2014-04-01 to 2015-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 43290000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459017011690/abmd-20170331.xml#180922 Filing: 000156459017011690 Input fundies:CapitalExpenditure: 5188000 USD (2014-04-01 to 2015-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459017011690/abmd-20170331.xml#183667 Filing: 000156459017011690 The citation records this snapshot. The page link may show a newer release later.
2016 2015-04-01 – 2016-03-31	USD 38.15 million Exact value Exact value: 38147000 USD 2015-04-01 – 2016-03-31: 38147000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2016-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 38147000 USD Concept: fundies:NetIncome Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:NetIncome: 38147000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459018014310/abmd-20180331.xml#170446 Filing: 000156459018014310 The citation records this snapshot. The page link may show a newer release later.	USD 76.8 million Exact value Exact value: 76795000 USD 2015-04-01 – 2016-03-31: 76795000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2016-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 76795000 USD Concept: fundies:OperatingCashFlow Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 76795000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459018014310/abmd-20180331.xml#211086 Filing: 000156459018014310 The citation records this snapshot. The page link may show a newer release later.	USD 15.62 million Exact value Exact value: 15624000 USD 2015-04-01 – 2016-03-31: 15624000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2016-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 15624000 USD Concept: fundies:CapitalExpenditure Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2016-03-31&surface=latest&period_type=duration&start=2015-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15624000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459018014310/abmd-20180331.xml#213618 Filing: 000156459018014310 The citation records this snapshot. The page link may show a newer release later.	USD 61.17 million Calculation and evidence 76795000 − 15624000 USD Exact free cash flow: 61171000 USD 2015-04-01 – 2016-03-31: 76795000 USD · Inspect Operating Cash Flow · Source 2015-04-01 – 2016-03-31: 15624000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2016-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 61171000 USD Concept: free-cash-flow Period: 2015-04-01 to 2016-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 76795000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459018014310/abmd-20180331.xml#211086 Filing: 000156459018014310 Input fundies:CapitalExpenditure: 15624000 USD (2015-04-01 to 2016-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459018014310/abmd-20180331.xml#213618 Filing: 000156459018014310 The citation records this snapshot. The page link may show a newer release later.
2017 2016-04-01 – 2017-03-31	USD 52.12 million Exact value Exact value: 52116000 USD 2016-04-01 – 2017-03-31: 52116000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2017-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 52116000 USD Concept: fundies:NetIncome Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:NetIncome: 52116000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459019020329/abmd-20190331.xml#192796 Filing: 000156459019020329 The citation records this snapshot. The page link may show a newer release later.	USD 115.12 million Exact value Exact value: 115116000 USD 2016-04-01 – 2017-03-31: 115116000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2017-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 115116000 USD Concept: fundies:OperatingCashFlow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 115116000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459019020329/abmd-20190331.xml#233981 Filing: 000156459019020329 The citation records this snapshot. The page link may show a newer release later.	USD 50.42 million Exact value Exact value: 50415000 USD 2016-04-01 – 2017-03-31: 50415000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2017-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 50415000 USD Concept: fundies:CapitalExpenditure Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2017-03-31&surface=latest&period_type=duration&start=2016-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 50415000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459019020329/abmd-20190331.xml#236602 Filing: 000156459019020329 The citation records this snapshot. The page link may show a newer release later.	USD 64.7 million Calculation and evidence 115116000 − 50415000 USD Exact free cash flow: 64701000 USD 2016-04-01 – 2017-03-31: 115116000 USD · Inspect Operating Cash Flow · Source 2016-04-01 – 2017-03-31: 50415000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2017-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 64701000 USD Concept: free-cash-flow Period: 2016-04-01 to 2017-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 115116000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459019020329/abmd-20190331.xml#233981 Filing: 000156459019020329 Input fundies:CapitalExpenditure: 50415000 USD (2016-04-01 to 2017-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459019020329/abmd-20190331.xml#236602 Filing: 000156459019020329 The citation records this snapshot. The page link may show a newer release later.
2018 2017-04-01 – 2018-03-31	USD 112.17 million Exact value Exact value: 112170000 USD 2017-04-01 – 2018-03-31: 112170000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2018-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 112170000 USD Concept: fundies:NetIncome Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:NetIncome: 112170000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459020026547/abmd-10k_20200331.htm#2794469 Filing: 000156459020026547 The citation records this snapshot. The page link may show a newer release later.	USD 192.55 million Exact value Exact value: 192546000 USD 2017-04-01 – 2018-03-31: 192546000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2018-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 192546000 USD Concept: fundies:OperatingCashFlow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 192546000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459020026547/abmd-10k_20200331.htm#2558755 Filing: 000156459020026547 The citation records this snapshot. The page link may show a newer release later.	USD 55.86 million Exact value Exact value: 55863000 USD 2017-04-01 – 2018-03-31: 55863000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2018-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 55863000 USD Concept: fundies:CapitalExpenditure Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2018-03-31&surface=latest&period_type=duration&start=2017-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 55863000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459020026547/abmd-10k_20200331.htm#2587411 Filing: 000156459020026547 The citation records this snapshot. The page link may show a newer release later.	USD 136.68 million Calculation and evidence 192546000 − 55863000 USD Exact free cash flow: 136683000 USD 2017-04-01 – 2018-03-31: 192546000 USD · Inspect Operating Cash Flow · Source 2017-04-01 – 2018-03-31: 55863000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2018-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 136683000 USD Concept: free-cash-flow Period: 2017-04-01 to 2018-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 192546000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459020026547/abmd-10k_20200331.htm#2558755 Filing: 000156459020026547 Input fundies:CapitalExpenditure: 55863000 USD (2017-04-01 to 2018-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459020026547/abmd-10k_20200331.htm#2587411 Filing: 000156459020026547 The citation records this snapshot. The page link may show a newer release later.
2019 2018-04-01 – 2019-03-31	USD 259.02 million Exact value Exact value: 259016000 USD 2018-04-01 – 2019-03-31: 259016000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2019-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 259016000 USD Concept: fundies:NetIncome Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:NetIncome: 259016000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459021029314/abmd-10k_20210331.htm#2771245 Filing: 000156459021029314 The citation records this snapshot. The page link may show a newer release later.	USD 252.2 million Exact value Exact value: 252197000 USD 2018-04-01 – 2019-03-31: 252197000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2019-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 252197000 USD Concept: fundies:OperatingCashFlow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 252197000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459021029314/abmd-10k_20210331.htm#2532184 Filing: 000156459021029314 The citation records this snapshot. The page link may show a newer release later.	USD 44 million Exact value Exact value: 44004000 USD 2018-04-01 – 2019-03-31: 44004000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2019-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 44004000 USD Concept: fundies:CapitalExpenditure Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2019-03-31&surface=latest&period_type=duration&start=2018-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44004000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459021029314/abmd-10k_20210331.htm#2571574 Filing: 000156459021029314 The citation records this snapshot. The page link may show a newer release later.	USD 208.19 million Calculation and evidence 252197000 − 44004000 USD Exact free cash flow: 208193000 USD 2018-04-01 – 2019-03-31: 252197000 USD · Inspect Operating Cash Flow · Source 2018-04-01 – 2019-03-31: 44004000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2019-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 208193000 USD Concept: free-cash-flow Period: 2018-04-01 to 2019-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 252197000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459021029314/abmd-10k_20210331.htm#2532184 Filing: 000156459021029314 Input fundies:CapitalExpenditure: 44004000 USD (2018-04-01 to 2019-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000156459021029314/abmd-10k_20210331.htm#2571574 Filing: 000156459021029314 The citation records this snapshot. The page link may show a newer release later.
2020 2019-04-01 – 2020-03-31	USD 203.01 million Exact value Exact value: 203009000 USD 2019-04-01 – 2020-03-31: 203009000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2020-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 203009000 USD Concept: fundies:NetIncome Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:NetIncome: 203009000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2951031 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 314.92 million Exact value Exact value: 314920000 USD 2019-04-01 – 2020-03-31: 314920000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2020-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 314920000 USD Concept: fundies:OperatingCashFlow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 314920000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2658324 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 44.01 million Exact value Exact value: 44006000 USD 2019-04-01 – 2020-03-31: 44006000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2020-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 44006000 USD Concept: fundies:CapitalExpenditure Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2020-03-31&surface=latest&period_type=duration&start=2019-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 44006000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2706747 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 270.91 million Calculation and evidence 314920000 − 44006000 USD Exact free cash flow: 270914000 USD 2019-04-01 – 2020-03-31: 314920000 USD · Inspect Operating Cash Flow · Source 2019-04-01 – 2020-03-31: 44006000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2020-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 270914000 USD Concept: free-cash-flow Period: 2019-04-01 to 2020-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 314920000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2658324 Filing: 000095017022010402 Input fundies:CapitalExpenditure: 44006000 USD (2019-04-01 to 2020-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2706747 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.
2021 2020-04-01 – 2021-03-31	USD 225.53 million Exact value Exact value: 225525000 USD 2020-04-01 – 2021-03-31: 225525000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2021-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 225525000 USD Concept: fundies:NetIncome Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:NetIncome: 225525000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2949106 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 274.58 million Exact value Exact value: 274578000 USD 2020-04-01 – 2021-03-31: 274578000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2021-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 274578000 USD Concept: fundies:OperatingCashFlow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 274578000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2656459 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 53.38 million Exact value Exact value: 53383000 USD 2020-04-01 – 2021-03-31: 53383000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2021-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 53383000 USD Concept: fundies:CapitalExpenditure Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2021-03-31&surface=latest&period_type=duration&start=2020-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 53383000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2704502 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 221.2 million Calculation and evidence 274578000 − 53383000 USD Exact free cash flow: 221195000 USD 2020-04-01 – 2021-03-31: 274578000 USD · Inspect Operating Cash Flow · Source 2020-04-01 – 2021-03-31: 53383000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2021-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 221195000 USD Concept: free-cash-flow Period: 2020-04-01 to 2021-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 274578000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2656459 Filing: 000095017022010402 Input fundies:CapitalExpenditure: 53383000 USD (2020-04-01 to 2021-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2704502 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.
2022 2021-04-01 – 2022-03-31	USD 136.51 million Exact value Exact value: 136505000 USD 2021-04-01 – 2022-03-31: 136505000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Net Income: 136505000 USD Concept: fundies:NetIncome Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ANetIncome&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:NetIncome: 136505000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2947181 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 285.39 million Exact value Exact value: 285390000 USD 2021-04-01 – 2022-03-31: 285390000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Operating Cash Flow: 285390000 USD Concept: fundies:OperatingCashFlow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3AOperatingCashFlow&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 285390000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2654594 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 35.76 million Exact value Exact value: 35763000 USD 2021-04-01 – 2022-03-31: 35763000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Capital Expenditure: 35763000 USD Concept: fundies:CapitalExpenditure Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094/explain?concept=fundies%3ACapitalExpenditure&period=2022-03-31&surface=latest&period_type=duration&start=2021-04-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 35763000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2702238 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.	USD 249.63 million Calculation and evidence 285390000 − 35763000 USD Exact free cash flow: 249627000 USD 2021-04-01 – 2022-03-31: 285390000 USD · Inspect Operating Cash Flow · Source 2021-04-01 – 2022-03-31: 35763000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ABIOMED, Inc. · 2022-03-31 ABIOMED, Inc. (edgar:815094) Free cash flow: 249627000 USD Concept: free-cash-flow Period: 2021-04-01 to 2022-03-31 Values: Latest reported Published: 2026-11-02T13:36:55Z Snapshot: 1a19fa04b2d1396d18709607efd98998d82710950234e297690acbc30ce60033 Dimensions: Consolidated View: https://fundies.io/companies/edgar/815094?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 285390000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2654594 Filing: 000095017022010402 Input fundies:CapitalExpenditure: 35763000 USD (2021-04-01 to 2022-03-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/815094/000095017022010402/abmd-20220331.htm#2702238 Filing: 000095017022010402 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

261 filings · 4,444 latest values · 4,444 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000815094, 815094, ABMD, edgar:815094

Also known as ABIOMED INC, ABIOMED, INC., ABIOMED, Inc.

ABIOMED, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2022 2021-04-01 – 2022-03-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation